^
7d
CHARACTERISTIC OF MYELOID SARCOMA BY CANCER GENOME PROFILING AND ALGORITHM OF POTENTIAL BIOMARKERS FOR UTERINE MESENCHYMAL TUMOR. (PubMed, Georgian Med News)
In cancer treatment, contrast-enhanced MRI is useful for identifying the size and location of tumor masses. However, contrast-enhanced MRI does not lead to the diagnosis of tumor masses. Therefore, early blood tests and tumor biopsy results are important for differential diagnosis and early treatment decisions.
Journal
|
IL2 (Interleukin 2)
|
daunorubicin
9d
Tirabrutinib-anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance. (PubMed, Expert Opin Drug Metab Toxicol)
Our in vitro data demonstrate that tirabrutinib influences daunorubicin pharmacodynamics by targeting both metabolic and transport pathways. However, Chou - Talalay analysis highlights the importance of appropriate dosing to achieve therapeutic synergy in combination regimens.
Journal
|
AKR1C3 (Aldo-Keto Reductase Family 1 Member C3)
|
daunorubicin • Velexbru (tirabrutinib)
12d
Investigating of harmane, harmine, and norharman as inhibitors of MDR1 and MRP1 to overcome chemotherapy resistance in cancer cells. (PubMed, Sci Rep)
In conclusion, these alkaloids enhanced the sensitivity of EPG85.257RDB and A2780 cells to daunorubicin, likely through inhibition of drug efflux activity. These findings highlight β-carboline alkaloids as promising candidates for combination therapy in overcoming multidrug resistance in cancer.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1)
|
daunorubicin
20d
SQ3370-001: Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=53, Terminated, Shasqi, Inc. | N=145 --> 53 | Recruiting --> Terminated; Sponsor's decision
Enrollment change • Trial termination
|
SQ3370
21d
Acute Myeloid Leukemia Patients with High-Risk Karyotypes Benefit from Decitabine in Combination with Modified CAG. (PubMed, Biochem Genet)
This study aims to investigate the genetic characteristics of Acute Myeloid Leukemia (AML) patients and identify which patients derive the greatest benefit from a low-intensity regimen of decitabine combined with modified Cytarabine + Aclarubicin + Granulocyte Colony-Stimulating Factor (D-CAG) or intensive chemotherapy (IA regimen). Notably, older patients with complex or monosomal karyotypes exhibited longer median OS than their younger counterparts (P < 0.05). In conclusion, D-CAG may represent a more suitable therapeutic option for AML patients with high-risk karyotypic profiles.
Journal
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • TET2 (Tet Methylcytosine Dioxygenase 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
cytarabine • decitabine • aclarubicin
21d
CircRAD18 Regulates Daunorubicin Resistance in Acute Myeloid Leukemia Cells through MiR-185-5p/HDGF Axis (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Knocking down CircRAD18 can reduce HDGF expression by up-regulating miR-185-5p, thereby weakening DNR resistance in AML cells, inhibiting KG1a cell proliferation under DNR treatment, and promoting apoptosis.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • PCNA (Proliferating cell nuclear antigen) • miR-185 (MicroRNA 185) • HDGF (Heparin Binding Growth Factor)
|
daunorubicin
23d
Construction of genetically encoded biosensors for monitoring cytosolic and mitochondrial H2O2 in response to nanozymes in THP-1 cells. (PubMed, Biophys Rep)
Using this biosensor, we examined the dynamics of cytosolic and mitochondrial H2O2 in response to Daunorubicin, Fe3O4 nanozyme with Polyetherimide (PEI)- or Dextran (Dex)-modification, and Prussian blue nanozyme with different diameters. Results indicated that the particle size of PBNPs and surface modification of Fe3O4 play critical roles in their intracellular effects on the aspect of H2O2 modulation. The live-cell biosensors thus provide a powerful tool for detecting the variations of cytosolic and mitochondrial H2O2 in response to nanozymes, thereby facilitating a better understanding of the biological effects of nanozymes and their potential biomedical applications.
Journal
|
CAT (Catalase)
|
daunorubicin
28d
Carrier-Free Peptide-Daunorubicin-Small Interfering RNA Nanoassembly for Targeted Therapy of Acute Myeloid Leukemia. (PubMed, Cyborg Bionic Syst)
Notably, silencing LILRB4 not only promoted T cell maturation in spleen and lymph nodes but also enhanced T cell infiltration in tumor tissues. This study offered a highly promising therapeutic strategy for AML and other diseases.
Journal
|
LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
|
daunorubicin
1m
Identification of potential PI3Kγ inhibitors among FDA approved drugs using integrated computational and quantum chemical approaches. (PubMed, Sci Rep)
Among them, Epirubicin, Doxorubicin, and Daunorubicin; all anthracycline chemotherapy agents; are known to inhibit cancer progression by slowing or halting cell growth. Molecular dynamics simulations further validated the QSAR screening results, confirming that Epirubicin forms the most stable and tightly bound complex with PI3Kγ, with ΔGbind values of -3.81 kcal/mol for PI3Kγ-M192 and -4.47 kcal/mol for PI3Kγ-Epirubicin. These findings indicate that the QSAR model could function as a targeted screening tool, facilitating the identification of drugs with strong affinity for the PI3Kγ receptor, and ultimately improving the hit rate compared to random screening approaches.
FDA event • Journal
|
PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
|
doxorubicin hydrochloride • epirubicin • daunorubicin
1m
New trial
|
Venclexta (venetoclax) • idarubicin hydrochloride • Duoenda (mitoxantrone liposomal)
1m
Study on the Efficacy and Safety of Mitoxantrone Liposome-Containing Regimens in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in the Real World (ChiCTR2500111194)
P4, N=60, Recruiting, Tongji Hospital Affiliated to Tongji Medical College Huazhong University of Science and Technology; Tongji Hospital Affiliated to Tongji Medical Colle
New P4 trial • Real-world evidence
|
Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
1m
New P4 trial
|
Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)